Cortex's CEO to Speak at the Rodman & Renshaw 2nd Annual Global Healthcare Conference on May 4th, 2005 in Paris, France.IRVINE, Calif. -- Cortex Pharmaceuticals, Inc. (AMEX AMEX See: American Stock Exchange : COR) announced that Roger G. Stoll, Ph.D., Chairman, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. will speak at the Rodman & Renshaw 2nd Annual Global Healthcare Conference in Paris on Wednesday, May 4th at 10:30 AM (local time) at the Intercontinental Hotel. Cortex is one of 180 invited companies to present at this conference to be held May 4-5, 2005. Dr. Stoll will provide an update on Cortex's AMPAKINE(R) clinical development program, with specific details related to CX717 and discuss upcoming clinical milestones. AMPAKINE compounds amplify the effects of glutamate, the primary excitatory ex·ci·ta·tive or ex·ci·ta·to·ry adj. Causing or tending to cause excitation. Adj. 1. excitatory - (of drugs e.g. neurotransmitter in the brain responsible for higher-order behaviors and cognitive activities, such as, thinking, smelling, touching and memory. A live webcast of the presentation can be accessed by logging onto http://www.wsw.com/webcast/rrshq5/cor/ and a replay will be available for 45 days following the conference. About Cortex Pharmaceuticals: Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders. The Company is pioneering a class of proprietary pharmaceuticals called AMPAKINE compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer's disease. Many psychiatric diseases, including schizophrenia, occur as a result of imbalances in the brain's neurotransmitter system. These imbalances may be improved by using the AMPAKINE technology. Cortex has alliances with N.V. Organon or·ga·non or or·ga·num n. pl. or·ga·nons or or·ga·nums or or·ga·na 1. An organ. 2. A set of principles for use in scientific investigation. organon pl. organa [Gr.] organ. for the treatment of schizophrenia The concept of a cure as such in the treatment of schizophrenia remains controversial, as there is no consensus on the definition of "treatment" in the case of schizophrenia, although some criteria for the remission of symptoms have recently been suggested. and depression and with Les Laboratoires Servier for the development of AMPAKINE compounds to treat the neurodegenerative effects associated with aging and disease, including Mild Cognitive Impairment mild cognitive impairment (MCI), n memory loss generally associated with aging; does not affect normal independent functioning of an individual. , Alzheimer's disease and anxiety disorders. (http://www.cortexpharm.com/) |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion